Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AMP Health vs FlyteHealth

AMP Health
Graded #200

Higher grade

vs+7.499999999999993
FlyteHealth
Graded #364

Lower grade

The verdict

AMP Health takes it — 66.1/100 to 58.6/100.

AMP Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AMP Health offers compounded semaglutide (injectable and oral) from $199/mo and tirzepatide from $309/mo, plus a $79/mo subscription fee.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAMP Health +15
60
45
Dose & formulationAMP Health +48
88
40
Clinical oversightFlyteHealth +8
75
83
Labs & monitoringFlyteHealth +21
52
73
FulfillmentEven
62
62
Contract termsFlyteHealth +14
41
55
AMP Health · left barFlyteHealth · right bar

The numbers

MetricAMP HealthFlyteHealth
WeighScore66.1/10058.6/100
GradeCC
Scorecard rank#200#364
Semaglutide$199/mo (compounded)Not disclosed
Tirzepatide$309/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
AMP Health

Graded #200 · C

Strengths

  • Semaglutide in both injectable and oral formats
  • Tirzepatide available
  • 30-day satisfaction guarantee
  • Personal nutrition plan and health coaching included

Where it loses points

  • $79/mo subscription fee on top of medication ($278–$388/mo total)
  • No visible LegitScript or PCAB accreditation
  • No physical address disclosed
  • States served not disclosed
  • Brand Wegovy listed but out of stock
FlyteHealth

Graded #364 · C

Strengths

  • Care led by board-certified obesity-medicine physicians
  • Multidisciplinary team with NPs, dietitians, and care coordinators
  • Published outcomes of about 13 to 16 percent weight loss over 12 months
  • High GLP-1 medication adherence (around 86 percent in reported data)
  • Comprehensive cardiometabolic care beyond GLP-1 alone

Where it loses points

  • Distributed primarily via employers, payers, and health plans, not direct cash-pay
  • Access is largely gated behind employer or plan sponsorship
  • GLP-1 is prescribed only when appropriate, not guaranteed
  • Self-pay pricing is not publicly listed (contact required)
  • Less suited to consumers wanting fast direct-to-door GLP-1

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard